1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
(
- Contribution to journal › Article
- 2023
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
- 2020
-
Mark
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
(
- Contribution to journal › Article
-
Mark
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients
(
- Contribution to journal › Article
- 2018
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2017
-
Mark
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry
(
- Contribution to journal › Article
- 2016
-
Mark
No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
2016) In British Journal of Haematology(
- Contribution to journal › Article
-
Mark
PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033).
(
- Contribution to journal › Article
- 2011
-
Mark
Long term risk of infections in Hodgkin lymphoma long-term survivors.
(
- Contribution to journal › Letter
- 2010
-
Mark
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)
(
- Contribution to journal › Letter